CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Market Closed 12-20 16:00:00 EST

0.1080

-0.0020

-1.82%

盘后0.1124

+0.0044+4.07%

19:59 EST

High0.1200	Low0.1008	Vol4.81M
Open0.1050	D1 Closing0.1100	Amplitude17.45%
Mkt Cap6.21M	Tradable Cap6.09M	Total Shares57.49M
T/O528.01K	T/O Rate8.52%	Tradable Shares56.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":0.108,"timestamp":1734728400000,"preClose":0.11,"halted":0,"volume":4805642,"hourTrading":{"tag":"盘后","latestPrice":0.1124,"preClose":0.108,"latestTime":"19:59 EST","volume":206760,"amount":22653.0207,"timestamp":1734742788937},"delay":0,"floatShares":56377299,"shares":57486706,"eps":-86.82832,"marketStatus":"Market Closed","change":-0.002,"latestTime":"12-20 16:00:00 EST","open":0.105,"high":0.12,"low":0.1008,"amount":528012.850456,"amplitude":0.174545,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-86.82832,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":0.11,"preHourTrading":{"tag":"盘前","latestPrice":0.107,"preClose":0.11,"latestTime":"09:26 EST","volume":199755,"amount":21155.258024,"timestamp":1734704799498},"postHourTrading":{"tag":"盘后","latestPrice":0.1124,"preClose":0.108,"latestTime":"19:59 EST","volume":206760,"amount":22653.0207,"timestamp":1734742788937},"volumeRatio":0.7752602414886152},"requestUrl":"/m/hq/s/CNSP/tweets","defaultTab":"tweets","newsList":[{"id":"2489457407","title":"CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2489457407","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489457407?lang=en_us&edition=fundamental","pubTime":"2024-12-05 22:10","pubTimestamp":1733407800,"startTime":"0","endTime":"0","summary":"Live webcast discussion featuring internationally renowned Glioblastoma Multiforme  Key Opinion Leaders. Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure. HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET.Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although CNS believes t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-host-virtual-analyst-141000662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4135","HST","BK4007","CNS","BK4181","CNSP","BK4218","BK4585"],"gpt_icon":0},{"id":"2486087535","title":"CNS Pharmaceuticals presents update from ongoing study of berubicin","url":"https://stock-news.laohu8.com/highlight/detail?id=2486087535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486087535?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:15","pubTimestamp":1732544131,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-presents-update-from-ongoing-study-of-berubicin?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-presents-update-from-ongoing-study-of-berubicin?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNS","BK4007","CNSP","BK4135"],"gpt_icon":0},{"id":"2486957087","title":"CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486957087","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486957087?lang=en_us&edition=fundamental","pubTime":"2024-11-25 22:00","pubTimestamp":1732543200,"startTime":"0","endTime":"0","summary":"Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology . Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025. All grades of any reported adverse events and those of Grade 3-5 in severity occurring in more than 10% of patients are shown to be relatively similar in the Berubicin and Lomustine arms. A slightly greater percentage of patients with all grades or Grades 3-5 with anaemia, headache, and decrease in neutrophil counts were shown in patients receiving Berubicin, while","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-presents-ongoing-potentially-140000579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4139","BK4097","BK4007","DNA","BK4109","CNS","CNSP","SMP","BK4135","BK4124"],"gpt_icon":0},{"id":"2484675825","title":"CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484675825","media":"ACCESSWIRE","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484675825?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:55","pubTimestamp":1731938100,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX.For more information about SNO 2024, please visit the conference website.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme , an aggres","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-abstract-accepted-135500390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNSP","BK4135","BK4007","CNS"],"gpt_icon":0},{"id":"2483711033","title":"CNS Pharmaceuticals Q3 EPS $(0.25) Misses $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483711033","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483711033?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:13","pubTimestamp":1731680011,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.12) by 108.33 percent. This is a 99.54 percent increase over losses of $(54.14) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42009099/cns-pharmaceuticals-q3-eps-0-25-misses-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","CNSP"],"gpt_icon":0},{"id":"2482367047","title":"CNS Pharmaceuticals Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482367047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482367047?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:31","pubTimestamp":1731339117,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc  expected to post a loss of10cents a share - Earnings Preview CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to report resultson November 13 (estimated) for the period endi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL8N3MI15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP"],"gpt_icon":0},{"id":"2480258915","title":"CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2480258915","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480258915?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:15","pubTimestamp":1730729700,"startTime":"0","endTime":"0","summary":"Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller. HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment.As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme , the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.The Virtual Investor KOL Connect segment featuring CNS can be accessed here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-virtual-investor-141500687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4135","CNSP","CNS","KOL"],"gpt_icon":0},{"id":"2480183499","title":"CNS Pharmaceuticals Receives More Time to Regain Compliance With Nasdaq Listing Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480183499","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480183499?lang=en_us&edition=fundamental","pubTime":"2024-11-02 00:34","pubTimestamp":1730478857,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals  said Friday that a Nasdaq hearings panel has given it more time regain compliance with the exchange's minimum bid price requirement.The company said it was granted until March 11, 2025 to regain compliance with the listing rule.CNS shares were 1.3% higher in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":[".IXIC","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","LU2210149790.SGD","BK4135","IE00BKPKM429.USD","NQmain","IE00BGHQF748.EUR","CNSP","LU2210150020.SGD","BK4112","NDAQ","BK4585","CNS","BK4588","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2480852858","title":"CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2480852858","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480852858?lang=en_us&edition=fundamental","pubTime":"2024-11-01 21:00","pubTimestamp":1730466000,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme , an aggressive and incurab","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-granted-exception-nasdaq-130000273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD",".IXIC","LU2095319765.USD","BK4007","BK4135","BK4112","BK4588","CNS","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","CNSP","IE00B3QW5Z07.USD","BK4585"],"gpt_icon":0},{"id":"2477687495","title":"CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2477687495","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477687495?lang=en_us&edition=fundamental","pubTime":"2024-10-24 02:50","pubTimestamp":1729709400,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock  pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share.The closing of the offering is expected to occur on or about October 24, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $3 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.A.G.P./Alliance Global Partners is acting as sole placement agent","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-announces-pricing-3-185000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4135","BK4585","LU2095319765.USD","LU2210149790.SGD","BK4112","BK4007","LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD","CNS","CNSP","IE00BKPKM429.USD",".IXIC","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2477533045","title":"Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2477533045","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477533045?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:50","pubTimestamp":1729691400,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/10/41489449/dow-tumbles-over-250-points-boeing-posts-q3-loss","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK4122","BA","BK4175","APVO","BK4564","LU1435385759.SGD","BK4516","BK4139","LU0868494617.USD","TQQQ","PCOM","ANRO","BK4079","SQQQ","BK4551","BK4533","LU1880398471.USD","LU1883839398.USD","BK4588","NQmain","BK4583","CNSP","VRAX","LU0321505868.SGD","LU1585245621.USD",".IXIC","LRHC","LU0321505439.SGD","BK4134","IBM","BK4585","MNQmain","LU1880398554.USD","LU2326559502.SGD","QLD","BK4538","BK4579","LU1429558221.USD","QID","BK4187","LU1430594728.SGD","PSQ","BK4007","BK4534"],"gpt_icon":1},{"id":"2474743883","title":"CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2474743883","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474743883?lang=en_us&edition=fundamental","pubTime":"2024-10-10 21:00","pubTimestamp":1728565200,"startTime":"0","endTime":"0","summary":"Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust. HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. The segment can be accessed here.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiform","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-participates-virtual-investor-130000621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KOL","CNS","BK4007","BK4135","CNSP"],"gpt_icon":0},{"id":"2473201584","title":"CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2473201584","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473201584?lang=en_us&edition=fundamental","pubTime":"2024-10-08 21:15","pubTimestamp":1728393300,"startTime":"0","endTime":"0","summary":"Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET. HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 16,2024 at 4:00 PM ET.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications incl","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-participate-2024-healthcare-131500427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4211","HCSG","VIRI","BK4135","CNS","SMMF","BK4139","CNSP","BK4007"],"gpt_icon":0},{"id":"2469119499","title":"CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2469119499","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469119499?lang=en_us&edition=fundamental","pubTime":"2024-09-23 21:00","pubTimestamp":1727096400,"startTime":"0","endTime":"0","summary":"Webcast presentation on Wednesday, September 25th at 1:55 PM CEST. HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 24th Annual Biotech in Europe Forum on Wednesday, September 25, 2024 at 1:55 PM CEST in Basel, Switzerland.In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-present-24th-annual-130000090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4007","BK4179","CNS","CNSP","FET"],"gpt_icon":0},{"id":"2466270827","title":"CNS Pharmaceuticals - Regains Compliance With Nasdaq Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2466270827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466270827?lang=en_us&edition=fundamental","pubTime":"2024-09-12 21:09","pubTimestamp":1726146576,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240912:nFWN3KU0R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2466527088","title":"CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2466527088","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466527088?lang=en_us&edition=fundamental","pubTime":"2024-09-12 21:00","pubTimestamp":1726146000,"startTime":"0","endTime":"0","summary":"HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc.  , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on September 10, 2024, it received notice from The Nasdaq Stock Market LLC  that the Company has regained compliance with the equity requirement under Nasdaq's Listing Rule 5550, subject to Nasdaq Mandatory Panel Monitor related to the equity requirement for a period of one year. Now that the Company has regained compliance with Listing Rule 5550, Nasdaq has advised the Company that this matter is now closed.CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Qxw8V8jPKeVzH7_nzi2c.w--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/bdd404f4d491dff4236c8f8dba67064c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-regains-compliance-nasdaq-130000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210149790.SGD","BK4215","BK4585","PSQ","LU2095319765.USD","BK4135","EQR","IE00B64PRP62.GBP","NDAQ","BK4112","CNS","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","CNSP","SQQQ","LU2210150020.SGD","QLD","BK4007",".IXIC","MNQmain","QID","NQmain","IE00BKPKM429.USD","TQQQ"],"gpt_icon":1},{"id":"2466430137","title":"CNS Pharmaceuticals Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2466430137","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466430137?lang=en_us&edition=fundamental","pubTime":"2024-09-10 20:56","pubTimestamp":1725972960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNSP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2024 08:56 ET (12:56 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","CNSP"],"gpt_icon":0},{"id":"2466439213","title":"CNS Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2466439213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466439213?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:43","pubTimestamp":1725968618,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nFWN3KS11L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2464287033","title":"Ibn Announces Latest Episode of the Biomedwire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2464287033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464287033?lang=en_us&edition=fundamental","pubTime":"2024-09-03 20:00","pubTimestamp":1725364804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240903:nTUA9GPP7S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2464712870","title":"IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2464712870","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464712870?lang=en_us&edition=fundamental","pubTime":"2024-09-03 20:00","pubTimestamp":1725364800,"startTime":"0","endTime":"0","summary":"LOS ANGELES, Sept. 03, 2024  -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode ofThe BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bYQvcxcJKxZ9Naw2pZUDDw--~B/aD03MTg7dz0xMjc2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/a114a7e9ffad10fc4632c57f21bec6a2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibn-announces-latest-episode-biomedwire-120000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0164881194.USD","LU1868837565.USD","LU1868837722.USD","LU0066902890.USD","LU0264410563.USD","LU0143863784.USD","IBN","LU1102505762.USD","LU0823039010.USD","IE00B0JY6M65.USD","LU0143863198.USD","CNSP","BK4585","LU1868838027.USD","BK4548","LU0181495838.USD","CNS","IE00B7N09G41.SGD","BK4207","BK4135","LU0823038988.USD","SG9999004220.SGD","BK4535","LU0828237940.HKD","LU0251143458.SGD","LU0531971678.HKD","BK4523","IE00BYTNYM70.SGD","DBP","BK4588","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":0.0496},{"period":"1month","weight":-0.1262},{"period":"3month","weight":-0.2448},{"period":"6month","weight":-0.9455},{"period":"1year","weight":-0.9982},{"period":"ytd","weight":-0.9983}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.194164},{"month":2,"riseRate":0.4,"avgChangeRate":-0.000171},{"month":3,"riseRate":0.2,"avgChangeRate":-0.161933},{"month":4,"riseRate":0.4,"avgChangeRate":0.057823},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002034},{"month":6,"riseRate":0.4,"avgChangeRate":-0.170886},{"month":7,"riseRate":0.2,"avgChangeRate":-0.250938},{"month":8,"riseRate":0.4,"avgChangeRate":-0.098088},{"month":9,"riseRate":0,"avgChangeRate":-0.21514},{"month":10,"riseRate":0.2,"avgChangeRate":0.089289},{"month":11,"riseRate":0.6,"avgChangeRate":-0.043335},{"month":12,"riseRate":0,"avgChangeRate":-0.209143}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction